Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study will assess the change in the expression of FcεRI receptors of blood basophils and
dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in
adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal
therapy.